Crestor Versus Placebo in Subjects With Heart Failure
Phase 3
Completed
- Conditions
- Heart Failure
- Registration Number
- NCT00206310
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of the study is to investigate if rosuvastatin, added on top of all other medicines prescribed to subjects with symptomatic systolic heart failure, reduces the combined endpoint of cardiovascular death or non-fatal myocardial infarction or non-fatal stroke (time to first event)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 5013
Inclusion Criteria
- Chronic symptomatic systolic heart failure of ischaemic aetiology as judged by the investigator, optimal therapy for chronic symptomatic systolic heart failure according to the investigator
Exclusion Criteria
- Acute myocardial infarction within 6 months before randomization
- Treatment with any statin or other lipid lowering drug; or a medical condition that in the opinion of the investigator requires treatment with a statin or other lipid lowering drug
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method The primary objective of this study is to determine whether rosuvastatin reduces the combined endpoint of cardiovascular death or non-fatal myocardial infarction (MI) or non-fatal stroke (time to first event).
- Secondary Outcome Measures
Name Time Method The secondary objectives are to evaluate the effects of rosuvastatin on: Total mortality Any coronary event defined as the combined endpoint of sudden death or fatal or non-fatal MI or Percutaneous Transluminal Coronary Angioplasty (PTCA) or Coronary Artery Bypass Grafting (CABG) or defibrillation of ventricular fibrillation by an implant Cardiovascular mortality with cause-specific mortality for sudden death; fatal MI; and death from worsening heart failure Total number of hospitalizations for cardiovascular causes; for unstable angina; and for worsening heart failure
Trial Locations
- Locations (1)
Research Site
🇬🇧York, United Kingdom